Navigation Links
Jerome Wilson Joins PRA International's Late Phase Service Group

Dr. Jerome Wilson to serve as Lead Epidemiologist

RALEIGH, N.C., Oct. 27 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announced today the appointment of Dr. Jerome Wilson as Senior Medical Director of Late Phase Services. As the Lead Epidemiologist, Dr. Wilson is responsible for providing consulting services and developing post-marketing strategies for PRA clients.

PRA provides extensive Phase IV Post-Marketing services to pharmaceutical and biotech companies. The company has executed more than 150 Late Phase studies in 23 countries, recruiting over 126,000 patients in nearly 12,000 sites.

In addition to more than 15 years of scientific management experience in the pharmaceutical industry, Dr. Wilson served as Senior Interdisciplinary Scientist and Team Leader for Anthrax Therapeutics at the U.S. Department of Health and Human Services (HHS). For this role, the Biomedical Advanced Research and Development Authority Office recognized Dr. Wilson for distinguished service.

Dr. Wilson also served as Associate Director for Scientific Program Operations at the National Center on Minority Health and Health Disparities at the National Institutes of Health (NIH). He received the NIH Director's Award for his work on the Genome Wide Association Studies Policy Development Team.

Additionally, Dr. Wilson served as Senior Director/Team Leader of Outcomes Research at Pfizer and has held appointments at the Memorial Sloan-Kettering Cancer Center, the National Cancer Institute's Division of Cancer Epidemiology and Genetics, Howard University's Cancer Center, and Georgetown University's School of Medicine.

"We are pleased to add Dr. Wilson to our Late Phase Services team," commented Maria Harrison, Vice President of PRA Late Phase Services. "His expertise in the post-marketing field will serve as a tremendous benefit to our clients, and our team."

Dr. Wilson holds an A.B. Cum Laude from Dillard University, an A.M. from Harvard Medical School, and a Ph.D. from the University Of North Carolina School Of Public Health.

About PRA International

PRA International is a privately held, global Clinical Research Organization providing services through all phases of clinical development. We specialize in Oncology, CNS, respiratory/allergy diseases, cardiovascular and infectious diseases. PRA has supported over 2,100 clinical trials in more than 60 countries on six continents through our global offices. PRA's therapeutic expertise, global reach, and project experience with local knowledge enable our project teams to deliver consistent, timely, and reliable service for our clients. PRA's Late Phase Services group supports global and regional post-approval studies with management in North America and Europe.

To learn more about PRA International, please visit, email or call our Global Headquarters at +1 (919) 786-8200.

SOURCE PRA International
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
2. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
3. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
4. Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
5. Food and Beverage Giant Joins Kannapolis Research Center
6. Mark Sutherland Joins GenVault as Senior Vice President, Business Development
7. Chief Technology Officer Joins ACAMP
8. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
9. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
10. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
11. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont ... today that they have entered into a multiyear collaboration to identify and characterize ... with additional tools for gene editing across all applications. , Under the terms ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
Breaking Biology Technology:
(Date:8/15/2017)... Va. , Aug. 15 2017   ivWatch LLC , ... of intravenous (IV) therapy, today announced receipt of its ISO 13485 ... developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the ... "This is ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
Breaking Biology News(10 mins):